Laboratoire de Chimie de Coordination UPR 8241

Accueil > A la une

Conférence Dr Lucie Paloque, équipe V

vendredi 1er octobre 2021 - 11h00 - Auditorium Fernand Gallais

PNG - 96.9 ko

"Antiplasmodial drugs and resistance in malaria parasite"

The fight against malaria faces to the emergence and massive spread in Asia of resistance of the parasite Plasmodium falciparum to the antimalarial drugs artemisinins. Artemisinins are the core component of Artemisinin-based Combination Therapies (ACTs) combining an artemisinin derivative with another antimalarial molecule. In 2020, artemisinin-resistant parasites are now also reported in South-America, and in Africa where by 2040 artemisinin resistance will lead to an increase in the incidence of several million cases. Artemisinin resistance is tracking thanks to surveillance of delayed parasite clearance in patients associated to the search of the parasite k13 gene mutations. This resistance is unique in Plasmodium since based on ability of a sub-population of these mutated parasites to enter in a quiescent state during drug exposure and thus escape treatment. The end of the treatment allows these parasites to resume their proliferation. Thus artemisinin resistance leads also to selection of partner drugs resistance and finally to therapeutic failures. In this context, in order to develop new antiplasmodial drugs, my work focuses on the study of artemisinin resistance selection and mechanism, parasite metabolism during drug exposure, identification of therapeutic targets and elaboration of new pharmacological approaches.